奥美拉唑联合硫糖铝治疗慢性胃炎患儿的疗效及对血清炎症因子免疫功能的影响

Curative Efficacy of Omeprazole Combined with Aluminum Sulfatein in the treatment of Chronic Gastritis in Children and Effects on Serum Inflammatory Factors and Immune Function

目的:分析奥美拉唑联合硫糖铝治疗慢性胃炎患儿的疗效及对血清炎症因子、免疫功能的影响。方法:选择2016年9月至2018年9月我院收治的小儿慢性胃炎165例纳入本次研究,根据简单随机分组法分为观察组(n=85)和对照组(n=80)。对照组使用硫糖铝治疗,观察组在对照组的基础上加用奥美拉唑进行治疗。比较两组患者临床疗效、血清白细胞介素-8(IL-8)、白细胞介素-6(IL-6)、肿瘤坏死因子α(TNF-α)水平、免疫功能及不良反应发生情况。结果:两组总有效率分别为95.29%、83.75%,差异显著(P<0.05);治疗后,两组炎症因子均较治疗前显著改善,且两组患者治疗后血清IL-8、IL-6及TNF-α水平比较差异显著(P<0.05);治疗后,两组患者CD3+、CD4+及CD8+水平均较治疗前显著改善,且两组患者治疗后CD3+、CD4+及CD8+水平差异显著(P<0.05);两组不良反应总发生率分别为9.41%、13.75%,无显著差异(P>0.05)。结论:在小儿慢性胃炎患者中采用奥美拉唑与硫糖铝疗效显著,可有效改善炎症因子及免疫功能水平,值得推广应用。

Objective: To study the curative efficacy of Omeprazole combined with aluminum sulfatein in the treatment of chronic gastritis in children and its effects on the serum inflammatory factors and immune function. Methods:165 cases of pediatric chronic gastritis admitted to our hospital from September 2016 to September 2018 were selected for this study, the patients were divided into observation group(n=85) and control group(n=80) according to the simple random grouping method. The control group was treated with sucralfate and the observation group was treated with omeprazole on the basis of the control group. Clinical efficacy, serum interleukin-8(il-8), interleukin-6(il-6), tumor necrosis factor alpha(tnf-alpha), immune function and adverse reactions were compared between the two groups. Results:After treatment, the total effective rates of the two groups were 95.29% and 83.75%, respectively, with significant difference(P<0.05). After treatment, inflammatory factors in both groups were significantly improved compared with those before treatment, and serum il-8, il-6 and tnf-alpha levels in the two groups were significantly different after treatment(P<0.05). After treatment, the levels of CD3+, CD4+ and CD8+ in the two groups were significantly improved compared with that before treatment, and the levels of CD3+, CD4+ and CD8+ in the two groups were significantly different after treatment(P<0.05). The total incidence of adverse reactions in the two groups was 9.41% and 13.75%, respectively, with no significant difference(P>0.05). Conclusion: The use of omeprazole and sucralate in children with chronic gastritis has significant curative effect and can effectively improve the level of inflammatory factors and immune function, which is worthy of promotion and application.